Overview

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Status:
NOT_YET_RECRUITING
Trial end date:
2036-04-01
Target enrollment:
Participant gender:
Summary
Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.
Phase:
PHASE2
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborator:
USWM, LLC (dba US WorldMeds)
Treatments:
Cisplatin
Cyclophosphamide
Doxorubicin
Eflornithine
Etoposide
Ifosfamide
Methotrexate
Topotecan
Vincristine